All news articles for October 2022

© GettyImages/Yuuji

Lonza expands team, labs for cell and gene development

By Jane Byrne

Lonza is to increase the size of the cell and gene therapy (CGT) development space at its Houston facility; the expansion will include viral vector-based process development and analytical development laboratories.

Pic:getty/sdecoret

CPhI Frankfurt: 5 ways to make the most of the event

By staff reporter

CPhI Frankfurt takes place next week: covering the full supply chain from research and manufacturing to packaging and finished products. Here’s five ideas on how to make the most of the event.

© george tsartsianidis / Getty Images

CPHI Pharma Award finalists announced

The awards cover innovations spanning the full pharmaceutical supply chain and feature many of pharma’s biggest names and breakthrough companies.

Pic:getty/kotofeja

New Alzheimer’s treatment buoyed by US Fast Track Designation

By Rachel Arthur

Acumen Pharmaceuticals believes ACU193 – the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβO) – offers the promise of an effective treatment with a better safety profile than other Alzheimer's...

Pic:getty/digitalvision

Syncona to acquire Applied Genetic Technologies Corporation

By Rachel Arthur

London investment fund Syncona will acquire retinal gene therapy company Applied Genetic Technologies Corporation (AGTC): with AGTC noting it had been facing ‘significant challenges’ in funding operations beyond 2022.

Pic:getty/callistaimages

AbbVie acquires DJS Antibodies

By Rachel Arthur

AbbVie will acquire DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins.

© GettyImages/skodonnell

Pfizer to raise COVID-19 vaccine price in US

By Jane Byrne

As the US government stops buying COVID-19 shots, Pfizer said the vaccine it developed with BioNTech will be sold for US$110 to US$130 per dose, from as early as the first quarter 2023.

Dementia research lags behind the disease burden, says the WHO report. Pic: getty/nopparit

How can dementia drug development be improved?

By Rachel Arthur

The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.

Pic:getty/mehmethilmibarcin

Lilly to acquire gene therapy company Akouos

By Rachel Arthur

Eli Lilly and Company will acquire Akouos, a precision genetic medicine company developing a portfolio of adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.

© GettyImages/Dr_Microbe

Charles River looks to speed up viral vector manufacturing

By Jane Byrne

Charles River Laboratories International has launched a new AAV based platform that it claims has the capability to reduce time from process development to GMP by 55% and deliver a drug product in fewer than eight months.

Melbourne wants to become an mRNA hub, with investments from both BioNTech & Moderna. Pic: getty/walterbibikow

BioNTech to build mRNA center in Australia

By Rachel Arthur

BioNTech will establish an mRNA research and innovation center in Victoria, alongside clinical scale manufacturing capabilities. Meanwhile, it has also pledged to step up clinical development of oncology therapies in the country.

Pic:getty/MG

EMA pilot to provide regulatory support to selected ATMP developers

By Rachel Arthur

The European Medicines Agency (EMA) will provide up to five selected advanced therapy medicinal products (ATMPs) with enhanced regulatory support - and in the process hopes to learn how to improve the regulatory processes for other ATMP drugs in the future.

Follow us

Products

View more

Webinars